TEAEs in the safety population
| TEAEs, n (%) . | KdD n = 308 . | Kd n = 153 . | ||
|---|---|---|---|---|
| Any grade∗ . | Grade ≥3† . | Any grade∗ . | Grade ≥3† . | |
| All TEAEs | 306 (99.4) | 273 (88.6) | 149 (97.4) | 120 (78.4) |
| Hematologic TEAEs | ||||
| Thrombocytopenia | 119 (38.6) | 76 (24.7) | 46 (30.1) | 25 (16.3) |
| Anemia | 114 (37.0) | 54 (17.5) | 52 (34.0) | 25 (16.3) |
| Neutropenia | 49 (15.9) | 31 (10.1) | 15 (9.8) | 10 (6.5) |
| Lymphopenia | 29 (9.4) | 22 (7.1) | 13 (8.5) | 11 (7.2) |
| Nonhematologic TEAEs | ||||
| Diarrhea | 118 (38.3) | 18 (5.8) | 28 (18.3) | 1 (0.7) |
| Hypertension | 115 (37.3) | 72 (23.4) | 49 (32.0) | 27 (17.6) |
| Upper respiratory tract infection | 105 (34.1) | 12 (3.9) | 37 (24.2) | 2 (1.3) |
| Fatigue | 81 (26.3) | 25 (8.1) | 29 (19.0) | 7 (4.6) |
| Pneumonia | 79 (25.6) | 57 (18.5) | 24 (15.7) | 14 (9.2) |
| Dyspnea | 70 (22.7) | 16 (5.2) | 35 (22.9) | 4 (2.6) |
| Pyrexia | 66 (21.4) | 6 (1.9) | 27 (17.6) | 2 (1.3) |
| Insomnia | 64 (20.8) | 16 (5.2) | 19 (12.4) | 3 (2.0) |
| Back pain | 63 (20.5) | 7 (2.3) | 21 (13.7) | 2 (1.3) |
| Nausea | 62 (20.1) | 0 | 22 (14.4) | 1 (0.7) |
| Hyperglycemia | 31 (10.1) | 16 (5.2) | 13 (8.5) | 5 (3.3) |
| Cataract | 34 (11.0) | 15 (4.9) | 13 (8.5) | 8 (5.2) |
| Events of interest | ||||
| Respiratory tract infection | 243 (78.9) | 117 (38.0) | 90 (58.8) | 27 (17.6) |
| Infusion reaction (on same day as any carfilzomib) | 142 (46.1) | 47 (15.3) | 50 (32.7) | 12 (7.8) |
| Peripheral neuropathy | 66 (21.4) | 6 (1.9) | 15 (9.8) | 1 (0.7) |
| Cardiac failure | 29 (9.4) | 12 (3.9) | 17 (11.1) | 13 (8.5) |
| Acute renal failure | 25 (8.1) | 11 (3.6) | 14 (9.2) | 10 (6.5) |
| Ischemic heart disease | 19 (6.2) | 16 (5.2) | 8 (5.2) | 5 (3.3) |
| TEAEs, n (%) . | KdD n = 308 . | Kd n = 153 . | ||
|---|---|---|---|---|
| Any grade∗ . | Grade ≥3† . | Any grade∗ . | Grade ≥3† . | |
| All TEAEs | 306 (99.4) | 273 (88.6) | 149 (97.4) | 120 (78.4) |
| Hematologic TEAEs | ||||
| Thrombocytopenia | 119 (38.6) | 76 (24.7) | 46 (30.1) | 25 (16.3) |
| Anemia | 114 (37.0) | 54 (17.5) | 52 (34.0) | 25 (16.3) |
| Neutropenia | 49 (15.9) | 31 (10.1) | 15 (9.8) | 10 (6.5) |
| Lymphopenia | 29 (9.4) | 22 (7.1) | 13 (8.5) | 11 (7.2) |
| Nonhematologic TEAEs | ||||
| Diarrhea | 118 (38.3) | 18 (5.8) | 28 (18.3) | 1 (0.7) |
| Hypertension | 115 (37.3) | 72 (23.4) | 49 (32.0) | 27 (17.6) |
| Upper respiratory tract infection | 105 (34.1) | 12 (3.9) | 37 (24.2) | 2 (1.3) |
| Fatigue | 81 (26.3) | 25 (8.1) | 29 (19.0) | 7 (4.6) |
| Pneumonia | 79 (25.6) | 57 (18.5) | 24 (15.7) | 14 (9.2) |
| Dyspnea | 70 (22.7) | 16 (5.2) | 35 (22.9) | 4 (2.6) |
| Pyrexia | 66 (21.4) | 6 (1.9) | 27 (17.6) | 2 (1.3) |
| Insomnia | 64 (20.8) | 16 (5.2) | 19 (12.4) | 3 (2.0) |
| Back pain | 63 (20.5) | 7 (2.3) | 21 (13.7) | 2 (1.3) |
| Nausea | 62 (20.1) | 0 | 22 (14.4) | 1 (0.7) |
| Hyperglycemia | 31 (10.1) | 16 (5.2) | 13 (8.5) | 5 (3.3) |
| Cataract | 34 (11.0) | 15 (4.9) | 13 (8.5) | 8 (5.2) |
| Events of interest | ||||
| Respiratory tract infection | 243 (78.9) | 117 (38.0) | 90 (58.8) | 27 (17.6) |
| Infusion reaction (on same day as any carfilzomib) | 142 (46.1) | 47 (15.3) | 50 (32.7) | 12 (7.8) |
| Peripheral neuropathy | 66 (21.4) | 6 (1.9) | 15 (9.8) | 1 (0.7) |
| Cardiac failure | 29 (9.4) | 12 (3.9) | 17 (11.1) | 13 (8.5) |
| Acute renal failure | 25 (8.1) | 11 (3.6) | 14 (9.2) | 10 (6.5) |
| Ischemic heart disease | 19 (6.2) | 16 (5.2) | 8 (5.2) | 5 (3.3) |